Aurobindo Pharma’s arm expands marketing, distribution agreement with Orion Corporation

11 Jan 2022 Evaluate

Aurobindo Pharma’s subsidiary company -- CuraTeQ Biologics (CuraTeQ) has expanded the scope of its marketing and distribution agreement with Orion Corporation (Orion) to commercialize its biosimilars pipeline to include the Baltic states in Europe. Earlier in 2020, CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia.

Under the terms of the agreement, Orion will be responsible for commercialization of CuraTeQ’s biosimilar products, currently in various stages of development/filing for the partnered territories. CuraTeQ will leverage Aurobindo’s established commercial presence in the nine European markets, including United Kingdom, France, Germany, Spain, Italy, Portugal to commercialise the biosimilar products in these markets (non-partnered).

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1131.05 -9.10 (-0.80%)
29-Jan-2026 10:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1588.45
Dr. Reddys Lab 1195.80
Cipla 1311.35
Zydus Lifesciences 883.50
Lupin 2099.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×